Eiger BioPharmaceuticals (NASDAQ:EIGR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

The company has a 50-day moving average price of $4.85 and a two-hundred day moving average price of $7.03. Eiger BioPharmaceuticals has a 1-year low of $1.10 and a 1-year high of $43.35. The stock has a market cap of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.